New Review Emphasizes the Importance of Menopause Support for Autistic Individuals
A Swansea University review highlights the critical need for tailored menopause support for autistic individuals, revealing gaps in knowledge, healthcare, and support systems and calling for targeted resources and interventions.
A comprehensive review conducted by Swansea University academics sheds light on the critical need for tailored menopause support for autistic people. The study reveals significant gaps in existing knowledge, healthcare provisions, and support mechanisms, emphasizing the importance of developing targeted resources and interventions.
Led by Dr. Aimee Grant from the University’s School of Health and Social Care, the review published in the journal Autism in Adulthood analyzed academic research and firsthand accounts to explore the menopause experiences of autistic individuals. The findings highlight three main issues: a widespread lack of awareness about menopause among autistic people, a broad spectrum of symptoms coupled with inadequate treatment options, and varying levels of support provided during this stage of life.
Many autistic women and individuals were unaware of menopause symptoms until they experienced changes, often turning to online forums and peer groups for information and support. The review documents a wide range of symptoms including mental health challenges, cognitive difficulties, fatigue, sleep disturbances, hot flashes, and night sweats. Increased sensory sensitivities can exacerbate these symptoms, leading to heightened overwhelm and distress. Some studies reported that menopause symptoms were more severe in autistic women compared to non-autistic counterparts, and these symptoms impacted their work, relationships, and self-esteem.
The support received by autistic individuals during menopause varies greatly, with many adopting non-medical coping strategies like increased rest. Interactions with healthcare professionals were frequently described as negative, and very few participants had tried hormone replacement therapy (HRT). The review emphasizes the need for more research in several key areas: understanding menopause’s impact on underserved autistic groups, urogenital symptoms such as urinary incontinence, the effectiveness of HRT, and the development of tools to assist autistic people through menopause.
Dr. Grant advocates for the creation of high-quality, co-produced resources to help autistic people navigate menopause, including exploring peer support models and providing healthcare professionals with tailored training. Willow Holloway, Director of Autistic UK, echoes this sentiment, stressing the importance of recognizing the unique communication and access needs of autistic individuals during menopause and involving lived experiences in developing effective solutions.
This review underscores an urgent call to action for healthcare systems and communities to better support autistic people through menopause, ensuring equitable care and informed interventions.
Source: [https://medicalxpress.com/news/2025-09-highlights-menopause-autistic-people.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Highlights Critical Gaps in Child Passenger Safety in U.S. Car Crashes
A new study shows that nearly 70% of children in fatal U.S. car crashes were not properly restrained, highlighting critical safety gaps and regional disparities that need urgent attention.
Is It Safe to Sit on Public Toilet Seats?
Understanding the risks associated with public toilet seats and how to practice safe hygiene can help prevent infections and make your bathroom visits less stressful.
FDA Approves Zynyz as First-Line Therapy for Advanced Anal Cancer
The FDA has approved Zynyz, a PD-1 inhibitor, as the first-line treatment for advanced anal cancer, offering new hope for patients with limited options and demonstrating significant clinical benefits based on recent trial results.
Blood Biomarker Could Foretell MS Relapses Through Blood Testing
New research highlights how blood levels of neurofilament light chain can predict multiple sclerosis relapses up to a year in advance, enabling earlier and more personalized treatment strategies.